Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

Advances in™ Hematology: Making Sense of Recent AML Approvals and Late-Stage Compounds

Release Date: December 30, 2018
Expiration Date: December 30, 2019
Media: Internet - based

Activity Overview

This educational program features video interviews with some of the top experts in acute myeloid leukemia (AML) addressing the pathophysiology of AML, best practices for assessing genomic and karyotypic changes in AML, and reviewing the latest clinical data supporting the use of 8 medications recently approved in AML, as well as other medications in late-stage therapeutic development.

Benefits of Completing Activity:

By participating in this exciting program, you will:

  • Learn best practices for risk stratification in patient with AML including essential genetic and karyotypic tests
  • Hear best practices in the use of current treatments in AML from top experts in the field
  • Explore clinical data supporting novel treatment approaches and best practices for use of available treatments

Acknowledgement of Commercial Support

This activity is supported by educational grants from Celgene Corporation and Takeda Oncology.

Instructions for This Activity and Receiving Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, educational content/audio files will be available for your reference.
  • In order to receive a CME certificate, you must complete the activity.
  • Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME certificate upon completion of these steps.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, and pathologists who treat patients with acute myeloid leukemia (AML). Nurses, nurse practitioners, physician assistants, pharmacists, and other healthcare professionals interested in the treatment of AML are also invited to participate.

Educational Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Identify testing strategies used to stratify risk and identify mutations in patients with acute myeloid leukemia (AML), including the findings’ impact on clinical decision-making
  • Utilize recent evidence-based recommendations concerning the use of testing strategies in AML treatment settings
  • Describe results from clinical trials that evaluated current and emerging strategies in patients with AML
  • Apply novel treatment approaches in the context of real-world clinical scenarios encountered in the management of AML

Faculty, Staff, and Planners' Disclosures


Amir T. Fathi
Amir T. Fathi, MD, MSc
Assistant Professor of Medicine
Harvard Medical School
Director, Leukemia Program
Massachusetts General Hospital
Boston, MA

Disclosures: Grant/Research Support: Takeda, Celgene, Agios; Consultant: Celgene, Agios, Takeda, Astellas, Daiichi Sankyo, Boston Biomedical, Jazz

Gabriel Mannis
Gabriel Mannis, MD
Co-Director, Cancer Immunotherapy Clinic
Helen Diller Family Comprehensive Cancer Center
Assistant Professor, Hematology/Blood and Marrow Transplantation
University of California, San Francisco
Hematologist, UCSF Medical Center
San Francisco, CA

Disclosures: Grant/Research Support: Agios, Leukemia & Lymphoma Society; Advisory Board: Kite, AbbVie/Genentech, Jazz

Eytan M. Stein, MD
Assistant Attending Physician
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY

Disclosures: Grant/Research Support: Bayer, Agios, Celgene, Syros; Consultant/Advisory Board: Bayer, Agios, Celgene, Syros, Pfizer, Novartis, Daiichi Sankyo, Astellas, Biolinene

The staff of PER® have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By